Drug Trial Radar · NCT05172245
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Sep 19, 2022
Primary completion
Jul 1, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Dec 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin, which is a chemotherapy used in this trial, is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib in combination with chemo-radiation may be better than chemo-radiation alone in treating patients with advanced head and neck cancer.
Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Head and Neck Carcinoma of Unknown Primary
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Locally Advanced Laryngeal Squamous Cell Carcinoma
- Locally Advanced Nasal Cavity Squamous Cell Carcinoma
- Locally Advanced Oral Cavity Squamous Cell Carcinoma
- Locally Advanced Oropharyngeal Squamous Cell Carcinoma
- Locally Advanced Paranasal Sinus Squamous Cell Carcinoma
- Locally Advanced Sinonasal Squamous Cell Carcinoma
- Maxillary Sinus Squamous Cell Carcinoma
- Stage III Hypopharyngeal Carcinoma AJCC v8
- Stage III Laryngeal Cancer AJCC v8
- Stage III Lip and Oral Cavity Cancer AJCC v8
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage III Sinonasal Cancer AJCC v8
- Stage IVA Hypopharyngeal Carcinoma AJCC v8
- Stage IVA Laryngeal Cancer AJCC v8
- Stage IVA Lip and Oral Cavity Cancer AJCC v8
- Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IVA Sinonasal Cancer AJCC v8
- Stage IVB Hypopharyngeal Carcinoma AJCC v8
- Stage IVB Laryngeal Cancer AJCC v8
- Stage IVB Lip and Oral Cavity Cancer AJCC v8
- Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IVB Sinonasal Cancer AJCC v8
Interventions
Biopsy ProcedureProcedure
Undergo tumor biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT or PET/CT
IpatasertibDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET/CT
Radiation TherapyRadiation
Undergo radiation therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) and recommended phase 2 dose of ipatasertib in combination with definitive chemo-radiationTime frame: At the completion of dose escalation phase, up to 56 days from treatment start date
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Kansas Clinical Research Center
Fairway, Kansas · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Active not recruiting
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Rutgers New Jersey Medical School
Newark, New Jersey · Recruiting
Montefiore Medical Center-Einstein Campus
The Bronx, New York · Recruiting
Montefiore Medical Center - Moses Campus
The Bronx, New York · Recruiting
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina · Active not recruiting
Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina · Active not recruiting
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio · Recruiting
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio · Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia · Suspended
VCU Massey Comprehensive Cancer Center
Richmond, Virginia · Recruiting
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada · Suspended
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.